How to buy Hoth Therapeutics stock | $1.65

Hoth Therapeutics, Inc is a biotechnology business based in the US. Hoth Therapeutics shares (HOTH) are listed on the NASDAQ and all prices are listed in US Dollars. Hoth Therapeutics employs 2 staff and has a market cap (total outstanding shares value) of USD$22.3 million.

How to buy shares in Hoth Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Hoth Therapeutics. Find the stock by name or ticker symbol: HOTH. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Hoth Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.65, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Hoth Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Hoth Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Hoth Therapeutics share price

Use our graph to track the performance of HOTH stocks over time.

Hoth Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$1.65
52-week range	USD$1.6 - USD$7.25
50-day moving average	USD$1.7136
200-day moving average	USD$2.2181
Wall St. target price	USD$9
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.493

Buy Hoth Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Hoth Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Hoth Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hoth Therapeutics price performance over time

Historical closes compared with the close of $1.65 from 2020-12-09

1 week (2021-01-11)	-21.80%
1 month (2020-12-18)	-0.60%
3 months (2020-10-16)	-7.82%
6 months (2020-07-17)	-44.82%

1 year (2020-01-17)	-67.09%
2 years (2019-01-15)	N/A
3 years (2018-01-15)	N/A
5 years (2016-01-15)	N/A

Hoth Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-126.6%
Return on equity TTM	-213.75%
Profit margin	0%
Book value	$0.4
Market capitalisation	USD$22.3 million

TTM: trailing 12 months

Shorting Hoth Therapeutics shares

There are currently 23,857 Hoth Therapeutics shares held short by investors – that's known as Hoth Therapeutics's "short interest". This figure is 101.5% up from 11,839 last month.

There are a few different ways that this level of interest in shorting Hoth Therapeutics shares can be evaluated.

Hoth Therapeutics's "short interest ratio" (SIR)

Hoth Therapeutics's "short interest ratio" (SIR) is the quantity of Hoth Therapeutics shares currently shorted divided by the average quantity of Hoth Therapeutics shares traded daily (recently around 265077.77777778). Hoth Therapeutics's SIR currently stands at 0.09. In other words for every 100,000 Hoth Therapeutics shares traded daily on the market, roughly 90 shares are currently held short.

However Hoth Therapeutics's short interest can also be evaluated against the total number of Hoth Therapeutics shares, or, against the total number of tradable Hoth Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hoth Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Hoth Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0024% of the tradable shares (for every 100,000 tradable Hoth Therapeutics shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hoth Therapeutics.

Find out more about how you can short Hoth Therapeutics stock.

Hoth Therapeutics share dividends

We're not expecting Hoth Therapeutics to pay a dividend over the next 12 months.

Hoth Therapeutics overview

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.

Frequently asked questions

• What percentage of Hoth Therapeutics is owned by insiders or institutions?

  Currently 37.886% of Hoth Therapeutics shares are held by insiders and 1.563% by institutions.

• How many people work for Hoth Therapeutics?

  Latest data suggests 2 work at Hoth Therapeutics.

• When does the fiscal year end for Hoth Therapeutics?

  Hoth Therapeutics's fiscal year ends in December.

• Where is Hoth Therapeutics based?

  Hoth Therapeutics's address is: 1 Rockefeller Plaza, New York, NY, United States, 10020

• What is Hoth Therapeutics's ISIN number?

  Hoth Therapeutics's international securities identification number is: US44148G1058

• What is Hoth Therapeutics's CUSIP number?

  Hoth Therapeutics's Committee on Uniform Securities Identification Procedures number is: 44148G105